JP2001514518A - 発現の向上したベクター並びにその製造および使用方法 - Google Patents
発現の向上したベクター並びにその製造および使用方法Info
- Publication number
- JP2001514518A JP2001514518A JP53956498A JP53956498A JP2001514518A JP 2001514518 A JP2001514518 A JP 2001514518A JP 53956498 A JP53956498 A JP 53956498A JP 53956498 A JP53956498 A JP 53956498A JP 2001514518 A JP2001514518 A JP 2001514518A
- Authority
- JP
- Japan
- Prior art keywords
- vector
- expression
- nucleic acid
- acid molecule
- transcription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Image Generation (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.特定の表現型を有する細胞中の少なくとも一つの第一の核酸分子の発現を向 上させるベクターであって、該ベクターが、該第一の核酸分子および転写因子 または転写因子と翻訳因子をコード化する少なくとも一つの第二の核酸分子を 含むように修飾されており、前記細胞の表現型に関して前記第一と第二の核酸 分子の実質的に同時の発現があり、それによって、該第二の核酸分子の発現が 、転写または転写と翻訳を向上させることにより、前記第一の核酸分子の発現 を向上させることを特徴とするベクター。 2.前記第一の核酸分子が第一のプロモータに操作可能に結合され、前記第二の 核酸分子が第二のプロモータに操作可能に結合され、該第一と第二のプロモー タが実質的に同時に機能的であることを特徴とする請求の範囲第1項記載のベ クター。 3.前記第一と第二の核酸分子が前記ベクター内の異なる遺伝子座にあることを 特徴とする請求の範囲第2項記載のベクター。 4.前記第一と第二の核酸分子が前記ベクター内の同じ遺伝子座にあることを特 徴とする請求の範囲第2項記載のベクター。 5.前記第一の核酸分子と前記第二の核酸分子が一つのプロモータに操作可能に 結合されていることを特徴とする請求の範囲第1項記載のベクター。 6.前記転写因子がポックスウイルス起源のものであることを特徴とする請求の 範囲第1項記載のベクター。 7.前記転写因子がワクシニアウイルスからのものであることを特徴とする請求 の範囲第6項記載のベクター。 8.前記転写因子が、H4L、D6、A7、G8R、A1L、A2L、H5R、 およびこれらの組合せからなる群より選択されるオープンリーディングフレー ムからのものであることを特徴とする請求の範囲第7項記載のベクター。 9.前記第二の核酸分子が、少なくとも一つの転写因子および少なくとも一つの 翻訳因子を含むことを特徴とする請求の範囲第1項記載のベクター。 10.前記翻訳因子が、eIF−2アルファリン酸化の阻害またはPKRリン酸化 の阻害を行って、もしくはそうでなければ、dsRNAを隔離して、dsRN Aの有効濃度を増大させることを特徴とする請求の範囲第1項記載のベクター 。 11.前記少なくとも一つの第二の核酸分子が、K3Lオープンリーディングフレ ーム、E3Lオープンリーディングフレーム、VAI RNAフレーム、EB ER RNANシグマ3オープンリーディングフレーム、TRBPオープンリ ーディングフレーム、およびそれらの組合せからなる群より選択されることを 特徴とする請求の範囲第10項記載のベクター。 12.前記第一の核酸分子が、関心のあるエピトープ、生体応答調整物質、成長因 子、認識配列、治療遺伝子および融合タンパク質からなる群より選択される分 子をコード化することを特徴とする請求の範囲第1項記載のベクター。 13.組換えウイルスであることを特徴とする請求の範囲第1項記載のベクター。 14.組換えポックスウイルスであることを特徴とする請求の範囲第13項記載のベ クター。 15.請求の範囲第1項記載のベクターを調製する方法であって、該ベクターを前 記少なくとも一つの第二の核酸分子を含むように修飾し、必要に応じて、該ベ クターを前記第一の核酸分子を含むように修飾して、それゆえ、前記細胞の表 現型に関して、該第一と第二の核酸分子の発現が実質的に同時である各工程を 含むことを特徴とする方法。 16.前記第一の核酸分子を第一のプロモータに、前記第二の核酸分子を第二のプ ロモータに操作可能に結合させる工程を含み、該第一と第二のプロモータが実 質的に同時に機能的であることを特徴とする請求の範囲第15項記載の方法。 17.前記第一と第二の核酸分子を一つのプロモータに操作可能に結合させる工程 を含むことを特徴とする請求の範囲第15項記載の方法。 18.請求の範囲第1項記載のベクターおよび製剤的に許容されるキャリヤまたは 希釈剤を含む免疫、ワクチンまたは治療組成物。 19.宿主内に免疫または治療応答を発生させる方法であって、該宿主に請求の範 囲第18項記載の組成物を投与する工程を含むことを特徴とする方法。 20.少なくとも一つの第一の核酸分子の発現を該第一の核酸分子を含むベクター により増大させる方法であって、該発現が特定の表現型を有する細胞内で行わ れ、該方法が、前記ベクターを、転写因子または転写因子と翻訳因子をコード 化する少なくとも一つの第二の核酸分子を含むように修飾する工程を含み、前 記細胞の表現型に関して、該第一と第二の核酸分子の発現が実質的に同時であ り、それによって、該第二の核酸分子の発現が、転写または転写と翻訳を向上 させることにより、該第一の核酸分子の発現を向上させることを特徴とする方 法。 21.遺伝子産物をインビトロで発現する方法であって、適切な細胞に請求の範囲 第1項記載のベクターを感染またはトランスフェクションさせる工程を含むこ とを特徴とする方法。 22.前記第一の核酸分子をインビボで発現させる方法であって、請求の範囲第1 項記載のベクターを宿主に投与する工程を含むことを特徴とする方法。 23.vCP1452またはvCP1433。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/816,155 US5990091A (en) | 1997-03-12 | 1997-03-12 | Vectors having enhanced expression, and methods of making and uses thereof |
US08/816,155 | 1997-03-12 | ||
PCT/US1998/002669 WO1998040501A1 (en) | 1997-03-12 | 1998-02-13 | Vectors having enhanced expression, and methods of making and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008212589A Division JP5405780B2 (ja) | 1997-03-12 | 2008-08-21 | 発現の向上したベクター並びにその製造および使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001514518A true JP2001514518A (ja) | 2001-09-11 |
Family
ID=25219820
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53956498A Pending JP2001514518A (ja) | 1997-03-12 | 1998-02-13 | 発現の向上したベクター並びにその製造および使用方法 |
JP2008212589A Expired - Lifetime JP5405780B2 (ja) | 1997-03-12 | 2008-08-21 | 発現の向上したベクター並びにその製造および使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008212589A Expired - Lifetime JP5405780B2 (ja) | 1997-03-12 | 2008-08-21 | 発現の向上したベクター並びにその製造および使用方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US5990091A (ja) |
EP (2) | EP1475443B1 (ja) |
JP (2) | JP2001514518A (ja) |
AT (1) | ATE486945T1 (ja) |
AU (1) | AU746402B2 (ja) |
CA (1) | CA2283537C (ja) |
DE (1) | DE69841986D1 (ja) |
DK (1) | DK1475443T3 (ja) |
WO (1) | WO1998040501A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534326A (ja) * | 2002-08-07 | 2005-11-17 | バヴァリアン・ノルディック・アクティーゼルスカブ | アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 |
WO2020076079A3 (ko) * | 2018-10-10 | 2020-10-15 | 주식회사 바이오리더스 | 락토바실러스 카제이 유래의 두 종류 프로모터를 이용한 두 가지 목적단백질의 동시 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 |
WO2023277069A1 (ja) * | 2021-06-30 | 2023-01-05 | 株式会社レプリテック | マイナス鎖rnaウイルスベクターの製造方法および製造されたマイナス鎖rnaウイルスベクター |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
ATE281844T1 (de) * | 1998-01-16 | 2004-11-15 | Univ Johns Hopkins | Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe |
US6762038B1 (en) * | 1998-09-09 | 2004-07-13 | The Cleveland Clinic Foundation | Mutant cell lines and methods for producing enhanced levels of recombinant proteins |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
WO2001045735A2 (en) * | 1999-12-21 | 2001-06-28 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
CA2416725A1 (en) * | 2000-04-27 | 2001-11-08 | Aventis Pasteur Limited | Immunizing against hiv infection |
DK1282702T3 (da) | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
US20110091428A1 (en) * | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
US7547674B2 (en) * | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
CA2416893A1 (en) * | 2000-07-31 | 2002-02-07 | Aventis Pasteur Limited | Modified cea and uses thereof |
US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
AU2001284695A1 (en) * | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
EP1317281A1 (fr) * | 2000-09-08 | 2003-06-11 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
FR2813793B1 (fr) * | 2000-09-08 | 2003-01-24 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
AU2001291225A1 (en) | 2000-09-26 | 2002-04-08 | Health Research Incorporated | Analysis of hiv-1 coreceptor use in the clinical care of hiv-1-infected patients |
CA2443266A1 (en) * | 2001-02-13 | 2002-08-22 | University Of Florida | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
WO2002070695A2 (en) * | 2001-03-05 | 2002-09-12 | Mount Sinai Hospital | Tumor associated proteins |
FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
DE10144664B4 (de) * | 2001-09-11 | 2005-06-09 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
WO2003063770A2 (en) | 2001-11-07 | 2003-08-07 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
US20050019752A1 (en) * | 2001-11-16 | 2005-01-27 | Genoveffa Franchini | Novel chimeric rev, tat, and nef antigens |
AU2002364161A1 (en) * | 2001-12-12 | 2003-06-23 | Aventis Pasteur Limited | Enhancement of the immune response using cd36-binding domain |
US20040241723A1 (en) * | 2002-03-18 | 2004-12-02 | Marquess Foley Leigh Shaw | Systems and methods for improving protein and milk production of dairy herds |
US7786278B2 (en) * | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US6952160B1 (en) * | 2002-08-07 | 2005-10-04 | Ford Global Technologies, Llc | Method and apparatus, for identifying the location of pressure sensors in a tire pressure monitoring system |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
US20040170646A1 (en) * | 2002-12-13 | 2004-09-02 | Aventis Pasteur, Inc. | Production of ALVAC on avian embryonic stem cells |
JP5052893B2 (ja) * | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
WO2004094454A2 (en) | 2003-04-18 | 2004-11-04 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
EP1689858B1 (en) | 2003-11-13 | 2013-05-15 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
US20050202484A1 (en) | 2004-02-19 | 2005-09-15 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
US7342107B2 (en) * | 2004-05-27 | 2008-03-11 | Centocor, Inc. | Cynomolgus prostate specific antigen |
CA2570563A1 (en) * | 2004-06-15 | 2006-09-28 | Centocor, Inc. | Method for screening agents against human prostate disease |
JP5449673B2 (ja) | 2004-10-08 | 2014-03-19 | クリヌベール、ファーマスーティカルズ、リミテッド | 対象者におけるメラニン形成を誘導するための組成物および方法 |
CN101208104B (zh) | 2005-04-25 | 2012-10-31 | 梅瑞尔有限公司 | Nipah病毒疫苗 |
JP2009512421A (ja) | 2005-08-15 | 2009-03-26 | ヴァクシン インコーポレイテッド | 非複製性ベクターワクチン投与による鳥類への免疫方法 |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
WO2007056614A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
US20090060947A1 (en) * | 2006-05-19 | 2009-03-05 | Sanofi Pasteur, Inc. | Immunological compositions |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
EP2056854A4 (en) * | 2006-08-28 | 2011-09-14 | Clinuvel Pharmaceuticals Ltd | METHOD FOR REDUCING THE INCIDENCE OR SPEED OF SKIN CANCER DEVELOPMENT AND ASSOCIATED PATHOLOGIES |
ES2525476T3 (es) | 2006-08-31 | 2014-12-23 | Clinuvel Pharmaceuticals Limited | Derivados de alfa-MSH para el tratamiento de fotodermatosis |
WO2008148068A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
WO2009062143A2 (en) * | 2007-11-09 | 2009-05-14 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof |
BRPI0908474A2 (pt) | 2008-02-12 | 2016-07-26 | Sanofi Pasteur Ltd | métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora |
SI2957292T1 (en) * | 2008-03-27 | 2018-04-30 | Clinuvel Pharmaceuticals Limited | Vitiligo therapy |
MX2011006922A (es) | 2008-12-24 | 2012-06-12 | Netherlands Vaccine Inst | Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia. |
EP2998315B2 (en) | 2009-04-03 | 2021-11-03 | Boehringer Ingelheim Animal Health USA Inc. | Newcastle disease virus vectored avian vaccines |
US9670506B2 (en) | 2009-04-30 | 2017-06-06 | Consejo Superior De Investigaciones Cientificas | Modified immunization vectors |
PL2611460T3 (pl) | 2010-08-31 | 2017-02-28 | Merial, Inc. | Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle |
WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
WO2012101509A2 (en) | 2011-01-28 | 2012-08-02 | Sanofi Pasteur Sa | Immunological compositions against hiv |
EP2487185A1 (en) | 2011-02-11 | 2012-08-15 | Clinuvel Pharmaceuticals Limited | Hexapeptide with improved activity in the repair of cellular DNA of dermal cells |
WO2012129295A1 (en) | 2011-03-21 | 2012-09-27 | Vaxin Inc. | Rapid and prolonged immunologic-therapeutic |
US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
CA2834288A1 (en) | 2011-04-25 | 2012-11-01 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
ES2674439T3 (es) | 2011-06-01 | 2018-06-29 | Merial, Inc. | Administración sin aguja de vacunas contra el VSRRP |
WO2013022991A2 (en) | 2011-08-08 | 2013-02-14 | Curelab Oncology, Inc. | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
DK2741740T3 (en) | 2011-08-12 | 2017-06-06 | Merial Inc | VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
WO2014012090A1 (en) | 2012-07-13 | 2014-01-16 | The Broad Institute, Inc. | Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof |
KR101484605B1 (ko) | 2012-07-25 | 2015-01-20 | 대한민국 | Bei로 불활화된 일본뇌염 바이러스 kv1899주 항원 및 돼지의 gm-csf 재조합 단백질을 포함하는 일본뇌염 불활화 백신 조성물 |
EP3808844A1 (en) | 2012-07-25 | 2021-04-21 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
EP2968514A1 (en) | 2013-03-12 | 2016-01-20 | Merial, Inc. | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
JP6821429B2 (ja) | 2013-09-25 | 2021-01-27 | ゾエティス・サービシーズ・エルエルシー | Pcv2b分岐ワクチン組成物及び使用方法 |
WO2015057671A1 (en) | 2013-10-14 | 2015-04-23 | The Broad Institute, Inc. | Artificial transcription factors comprising a sliding domain and uses thereof |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
RU2016128557A (ru) | 2013-12-29 | 2018-02-01 | Кьюрлаб Онколоджи, Инк. | МЕТОДЫ И КОМПОЗИЦИИ, СВЯЗАННЫЕ С p62 / SQSTM1, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ВОСПАЛЕНИЕМ |
US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
CA2990643C (en) | 2015-06-23 | 2023-10-17 | Merial, Inc. | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4738922A (en) * | 1984-05-25 | 1988-04-19 | Dana Farber Cancer Institute | Trans-acting transcriptional factors |
US5302517A (en) * | 1987-06-16 | 1994-04-12 | The Board Of Regents Of The University Of Nebraska | Method of controlling the expression of a gene in a cell culture, cell culture vector used in the method and method of making the vector |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
CA1307482C (en) * | 1987-11-09 | 1992-09-15 | Ronald G. Schoner | Vectors and expression sequences for production of polypeptides |
US5192669A (en) * | 1987-11-09 | 1993-03-09 | Eli Lilly And Company | Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences |
WO1990001550A1 (en) * | 1988-07-29 | 1990-02-22 | Zymogenetics, Inc. | High efficiency translation of polycistronic messages in eucaryotic cells |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
EP1156102A1 (en) * | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
JPH0638773A (ja) * | 1992-01-31 | 1994-02-15 | Toyobo Co Ltd | 薬剤耐性構造タンパク質遺伝子を選択遺伝子として用いた発現ベクター |
JPH06277074A (ja) * | 1993-03-31 | 1994-10-04 | Terumo Corp | 発現ベクター |
GB2299336A (en) * | 1993-12-23 | 1996-10-02 | Merck & Co Inc | Homologous recombination antibody expression sysstem for murine cells |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
EP1840209A3 (en) * | 1995-01-13 | 2008-03-05 | Virogenetics Corporation | Adeno-associated virus vectors and use thereof |
-
1997
- 1997-03-12 US US08/816,155 patent/US5990091A/en not_active Expired - Lifetime
-
1998
- 1998-02-13 DK DK04075152.1T patent/DK1475443T3/da active
- 1998-02-13 AT AT04075152T patent/ATE486945T1/de not_active IP Right Cessation
- 1998-02-13 CA CA002283537A patent/CA2283537C/en not_active Expired - Lifetime
- 1998-02-13 EP EP04075152A patent/EP1475443B1/en not_active Expired - Lifetime
- 1998-02-13 AU AU61584/98A patent/AU746402B2/en not_active Ceased
- 1998-02-13 EP EP98906338A patent/EP0970226A4/en not_active Withdrawn
- 1998-02-13 JP JP53956498A patent/JP2001514518A/ja active Pending
- 1998-02-13 DE DE69841986T patent/DE69841986D1/de not_active Expired - Lifetime
- 1998-02-13 WO PCT/US1998/002669 patent/WO1998040501A1/en not_active Application Discontinuation
- 1998-05-15 US US09/079,587 patent/US6130066A/en not_active Expired - Lifetime
-
2008
- 2008-08-21 JP JP2008212589A patent/JP5405780B2/ja not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534326A (ja) * | 2002-08-07 | 2005-11-17 | バヴァリアン・ノルディック・アクティーゼルスカブ | アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子 |
WO2020076079A3 (ko) * | 2018-10-10 | 2020-10-15 | 주식회사 바이오리더스 | 락토바실러스 카제이 유래의 두 종류 프로모터를 이용한 두 가지 목적단백질의 동시 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 |
WO2023277069A1 (ja) * | 2021-06-30 | 2023-01-05 | 株式会社レプリテック | マイナス鎖rnaウイルスベクターの製造方法および製造されたマイナス鎖rnaウイルスベクター |
WO2024004235A1 (ja) * | 2021-06-30 | 2024-01-04 | 株式会社レプリテック | マイナス鎖rnaウイルスベクターの製造方法および製造されたマイナス鎖rnaウイルスベクター |
Also Published As
Publication number | Publication date |
---|---|
US6130066A (en) | 2000-10-10 |
ATE486945T1 (de) | 2010-11-15 |
JP5405780B2 (ja) | 2014-02-05 |
EP0970226A4 (en) | 2002-06-12 |
WO1998040501A1 (en) | 1998-09-17 |
US5990091A (en) | 1999-11-23 |
DE69841986D1 (de) | 2010-12-16 |
AU6158498A (en) | 1998-09-29 |
EP1475443A2 (en) | 2004-11-10 |
EP0970226A1 (en) | 2000-01-12 |
CA2283537C (en) | 2009-04-28 |
CA2283537A1 (en) | 1998-09-17 |
EP1475443A3 (en) | 2004-12-01 |
DK1475443T3 (da) | 2011-02-21 |
EP1475443B1 (en) | 2010-11-03 |
AU746402B2 (en) | 2002-05-02 |
JP2008307056A (ja) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5405780B2 (ja) | 発現の向上したベクター並びにその製造および使用方法 | |
US6004777A (en) | Vectors having enhanced expression, and methods of making and uses thereof | |
JP4064466B2 (ja) | レンチウイルスから誘導した非相同挿入部分を含むポックスウイルスベースの発現ベクター | |
EP0979101B1 (en) | Recombinant canine adenovirus 2 (cav2) containing exogenous dna | |
JP3826055B2 (ja) | 組換えアビポックスウイルスによる免疫方法 | |
JP6316227B2 (ja) | 複数の相同ヌクレオチド配列を含むベクター | |
US20030013076A1 (en) | Parapoxvirus vectors | |
JP2004089185A (ja) | フラビウイルス組換えポックスウイルスワクチン | |
WO1998000166A9 (en) | Recombinant canine adenovirus (cav) containing exogenous dna | |
CA2110489A1 (en) | Immunodeficiency virus recombinant poxvirus vaccine | |
WO1994017810A1 (en) | Recombinant cytomegalovirus vaccine | |
JP2007105040A (ja) | 組換体ポックスウイルス−ネコ感染性腹膜炎ウイルス、その組成物およびそれらの製造および使用方法 | |
CA2583147C (en) | Chimeric vectors | |
JP3824619B2 (ja) | 麻疹ウイルス組換え体ポックスウイルスワクチン | |
JP3529146B2 (ja) | 組み換え体ネコヘルペスウイルスワクチン | |
JP3529134B2 (ja) | 組換えネコヘルペスウイルスのベクターワクチン | |
CA2259460C (en) | Recombinant canine adenovirus (cav) containing exogenous dna | |
AU775125B2 (en) | Truncated transcriptionally active cytomegalovirus promoters | |
CZ277921B6 (en) | Peptides and polypeptides, vaccines and nucleic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071009 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080722 |